Ticker: TSX – TOS
Shares Outstanding: 82,599,656
QUÉBEC, March 6, 2015 /CNW Telbec/ - TSO3 Inc. (TSX: TOS) ("TSO3" or the "Corporation") an innovator in sterilization technology for medical devices in healthcare settings, today announced that the Company has signed its first commercial agreement with Getinge Infection Control in support of the launch of the STERIZONE® VP4 Sterilization System. The non-exclusive agreement covers multiple markets in which Getinge has significant market share, including North America and other selected markets. Efforts to launch the product will begin immediately.
"We are extremely pleased to have Getinge Infection Control representing our STERIZONE® technology" stated R.M. (Ric) Rumble, President and CEO. "Our recent efforts which resulted in bolstering our balance sheet means that TSO3 has the financial resources available to support Getinge's sales efforts and after, sales service support. Getinge has watched the progression of our technology through the US regulatory process and with US clearance now in-hand, both organizations see the opportunity to launch this superior technology in North America and selected additional markets" concluded Mr Rumble.
"Getinge Infection Control is the world leader in sterile reprocessing of reusable medical devices" stated Mr. Andrew Ray, President and CEO of Getinge Infection Control North America. "The TSO3 technology fills a gap in our portfolio and is a natural fit for our commercial team. Our entire organization is anxious to get started assisting our mutual customers understand how this technology improves their process and reduces the cost of sterilization while improving patient outcomes" concluded Mr. Ray.
About the STERIZONE® VP4 low temperature Sterilizer
The STERIZONE® VP4 Sterilizer developed by TSO3 is a dual sterilant, low temperature sterilization system that utilizes vaporized hydrogen peroxide (H2O2) and ozone. Its single cycle can sterilize a large number and wide range of compatible devices, thereby allowing for cost effective error-free sterilization process. TSO3's unique Dynamic Sterilant Delivery SystemTM automatically adjusts the quantity of injected sterilant based on the load composition, weight and temperature. With its large 75-lbs load capacity and a short cycle time, the STERIZONE® VP4 Sterilizer can enhance throughput and lower sterilization cost. The STERIZONE® VP4 Sterilizer was cleared for commercialization in the United States in December 2014.
TSO3's activities encompass the sale, production, maintenance, research, development and licensing of sterilization processes, related consumable supplies and accessories for heat-sensitive medical devices. The Company designs products for sterile processing areas in the hospital environment that offer an advantageous replacement solution to other low temperature sterilization processes currently used in hospitals. It also offers services related to the maintenance of sterilization equipment and compatibility testing of medical devices with such processes.
For more information about TSO3, visit the Company's Web site at www.tso3.com.
The statements in this release and oral statements made by representatives of TSO3 relating to matters that are not historical facts (including, without limitation, those regarding the timing or outcome of any financing undertaken by TSO3) are forward-looking statements that involve certain risks, uncertainties and hypotheses, including, but not limited to, general business and economic conditions, the condition of the financial markets, the ability of TSO3 to obtain financing on favourable terms and other risks and uncertainties.
The TSX has neither approved nor disapproved the information contained herein and accepts no responsibility for it.
SOURCE TSO3 Inc.
For further information: R.M. (Ric) Rumble, President and CEO, (418) 651-0003, Email: email@example.com ; Paule De Blois, General Manager, Administration, (418) 651-0003, Email: firstname.lastname@example.org